Piper Jaffray Downgrades Third Wave (TWTI) to Neutral; Another Buyer Unlikely
More News related to HOLX
- Hologic (HOLX) Could See Pressure As Group Urges Mammograms at 50, Not 40
- Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009
- Hologic to Present at NASDAQ OMX 23rd Investor Program in London
- Xenomics, Inc. and Its Subsidiary TrovaGene, Inc. Announce HPV Patent Filing Based on Transrenal DNA Technology
- After-Hours Movers 11/09: SGK, PCLN, SQNM Higher; MBI, SDTH, UTK, TOPS, CPST, BTN, FLR Lower
More News related to TWTI
- Hologic (HOLX) Accepts Shares of Third Wave Technologies (TWTI)
- Deutsche Bank Downgrades Third Wave Technologies (TWTI) to Hold; Another Buyer Unlikely
- Piper Jaffray Downgrades Third Wave (TWTI) to Neutral; Another Buyer Unlikely
- Baird Downgrades Third Wave (TWTI) to Neutral
- Collins Stewart Downgrades Third Wave Technologies (TWTI) to Hold
Piper Jaffray downgrades Third Wave (NASDAQ: TWTI) from Buy to Neutral but raises their price target from $10.50 to $11.25.
Piper Jaffray believes that another buyer to emerge is unlikely. The firm's $11.25 price target is consistent with the offer price from Hologic (NASDAQ: HOLX).
The firm said, "We have previously written that we expect Third Wave to present their much-anticipated clinical data at the upcoming American Academy of Clinical Chemistry meeting in Washington this July. However, we now believe the odds of this are quite small and combined with what could well be a faster-than-expected close of the deal (due to the early termination of the Hart-Scott-Rodino Act), do not believe additional buyers are likely to emerge."
Third Wave Technologies, Inc. is a developer and manufacturer of molecularprobes and assays for research and clinical diagnostics.
Related Categories
DowngradesStocks Mentioned
-0.68
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
